Detalhe da pesquisa
1.
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib.
Anticancer Drugs
; 35(1): 86-88, 2024 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37227039
2.
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Future Oncol
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38357801
3.
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report.
Invest New Drugs
; 40(1): 190-193, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34436699
4.
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Future Oncol
; 18(7): 771-779, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35068173
5.
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC).
Int J Mol Sci
; 23(18)2022 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36142204
6.
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: a case report within the experience of a single institution.
Anticancer Drugs
; 32(7): 755-757, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33661187
7.
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines).
Curr Oncol Rep
; 23(11): 126, 2021 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34453261
8.
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis.
Future Oncol
; 17(32): 4415-4424, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34402681
9.
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Br J Cancer
; 123(1): 26-32, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32346071
10.
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.
Br J Cancer
; 120(1): 57-62, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30377342
11.
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event.
Invest New Drugs
; 36(1): 144-146, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28631096
12.
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Br J Cancer
; 125(2): 306, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34012035
13.
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome.
Tumori
; : 3008916241255485, 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38779904
14.
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Eur J Cancer
; 202: 114006, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38489861
15.
Immune-mediated cholangitis: is it always nivolumab's fault?
Cancer Immunol Immunother
; 67(8): 1325-1327, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29623342
16.
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY.
Immunotherapy
; 15(2): 85-91, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36628573
17.
Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis.
J Natl Cancer Inst
; 115(1): 29-42, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36322815
18.
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.
JCO Precis Oncol
; 7: e2300073, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37262392
19.
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors.
JTO Clin Res Rep
; 4(9): 100563, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37745898
20.
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC).
Diagnostics (Basel)
; 14(1)2023 Dec 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38201357